Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (104) 104
life sciences & biomedicine (103) 103
oncology (101) 101
humans (93) 93
female (59) 59
middle aged (52) 52
male (51) 51
aged (43) 43
respiratory system (41) 41
adult (39) 39
lung neoplasms - genetics (37) 37
lung neoplasms - pathology (35) 35
carcinoma, non-small-cell lung - genetics (31) 31
lung cancer (29) 29
lung neoplasms - drug therapy (29) 29
biological and medical sciences (27) 27
medical sciences (27) 27
prognosis (27) 27
pulmonary and respiratory medicine (26) 26
carcinoma, non-small-cell lung - drug therapy (25) 25
carcinoma, non-small-cell lung - pathology (24) 24
lung cancer, non-small cell (19) 19
neoplasm staging (19) 19
tumors (18) 18
aged, 80 and over (17) 17
cancer (17) 17
immunohistochemistry (17) 17
mutation (17) 17
non-small cell lung cancer (17) 17
pneumology (17) 17
tumors of the respiratory system and mediastinum (17) 17
care and treatment (15) 15
chemotherapy (15) 15
lung neoplasms - metabolism (15) 15
follow-up studies (14) 14
nsclc (14) 14
receptor, epidermal growth factor - genetics (14) 14
treatment outcome (14) 14
lung neoplasms - mortality (12) 12
protein kinase inhibitors - therapeutic use (12) 12
research (12) 12
antineoplastic agents (11) 11
antineoplastic agents - therapeutic use (11) 11
carcinoma, non-small-cell lung - mortality (11) 11
chemistry (11) 11
in situ hybridization, fluorescence (11) 11
pharmacology. drug treatments (11) 11
survival analysis (11) 11
survival rate (11) 11
beer (10) 10
biochemistry (10) 10
compositions or test papers therefor (10) 10
condition-responsive control in microbiological orenzymological processes (10) 10
disease-free survival (10) 10
enzymology (10) 10
hematology, oncology and palliative medicine (10) 10
lung neoplasms - diagnosis (10) 10
lung neoplasms - surgery (10) 10
measuring or testing processes involving enzymes, nucleicacids or microorganisms (10) 10
metallurgy (10) 10
metastasis (10) 10
microbiology (10) 10
mutation or genetic engineering (10) 10
processes of preparing such compositions (10) 10
spirits (10) 10
vinegar (10) 10
wine (10) 10
adenocarcinoma - genetics (9) 9
analysis (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
carcinoma, non-small-cell lung - metabolism (9) 9
carcinoma, non-small-cell lung - surgery (9) 9
gene dosage (9) 9
lung cancer, small cell (9) 9
prospective studies (9) 9
quinazolines - therapeutic use (9) 9
receptor, epidermal growth factor - antagonists & inhibitors (9) 9
europe (8) 8
gene expression regulation, neoplastic (8) 8
investigating or analysing materials by determining theirchemical or physical properties (8) 8
lung neoplasms - therapy (8) 8
measuring (8) 8
patients (8) 8
physics (8) 8
radiotherapy (8) 8
small cell lung cancer (8) 8
testing (8) 8
abridged index medicus (7) 7
biomarkers, tumor - analysis (7) 7
disease progression (7) 7
epidermal growth factor receptor (7) 7
lung neoplasms - radiotherapy (7) 7
non-small cell lung carcinoma (7) 7
predictive value of tests (7) 7
proto-oncogene proteins - genetics (7) 7
radiology, nuclear medicine & medical imaging (7) 7
retrospective studies (7) 7
antineoplastic agents - adverse effects (6) 6
brain neoplasms - secondary (6) 6
carcinoma, non-small-cell lung - secondary (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Whole Brain Radiotherapy for Patients with Non–Small Cell Lung Cancer with EGFR Mutations—Why and When?
by Dziadziuszko, Rafal
Journal of thoracic oncology, ISSN 1556-0864, 10/2016, Volume 11, Issue 10, pp. 1604 - 1605
Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
by Zimmermann, Stefan and Dziadziuszko, Rafal and Peters, Solange
Cancer treatment reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 716 - 722
Hematology, Oncology and Palliative Medicine | Non small cell lung cancer (NSCLC) | Driver oncogenes | Targeted treatment | Brain metastasis | Stereotactic radiotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Neurology | Tumors of the nervous system. Phacomatoses | Pharmacology. Drug treatments | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Pneumology | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - surgery | Prognosis | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Radiosurgery | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Treatment Outcome | Brain Neoplasms - drug therapy | Brain Neoplasms - surgery | Incidence | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Molecular Targeted Therapy - methods | Blood-Brain Barrier | Lung cancer, Small cell | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
by Peters, Solange and Camidge, D. Ross and Shaw, Alice T and Gadgeel, Shirish and Ahn, Jin S and Kim, Dong-Wan and Ou, Sai-Hong I and Pérol, Maurice and Dziadziuszko, Rafal and Rosell, Rafael and Zeaiter, Ali and Mitry, Emmanuel and Golding, Sophie and Balas, Bogdana and Noe, Johannes and Morcos, Peter N and Mok, Tony and ALEX Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Radiotherapy and targeted drugs
by Dziadziuszko, Rafal
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 2012, Volume 77, pp. S2 - S2
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
by Sequist, Lecia V and Soria, Jean-Charles and Goldman, Jonathan W and Wakelee, Heather A and Gadgeel, Shirish M and Varga, Andrea and Papadimitrakopoulou, Vassiliki and Solomon, Benjamin J and Oxnard, Geoffrey R and Dziadziuszko, Rafal and Aisner, Dara L and Doebele, Robert C and Galasso, Cathy and Garon, Edward B and Heist, Rebecca S and Logan, Jennifer and Neal, Joel W and Mendenhall, Melody A and Nichols, Suzanne and Piotrowska, Zofia and Wozniak, Antoinette J and Raponi, Mitch and Karlovich, Chris A and Jaw-Tsai, Sarah and Isaacson, Jeffrey and Despain, Darrin and Matheny, Shannon L and Rolfe, Lindsey and Allen, Andrew R and Camidge, D. Ross
The New England journal of medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
by Jassem, Jacek and Dziadziuszko, Rafał
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 916 - 917
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Taxoids - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Humans | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
by McCoach, Caroline E and Le, Anh T and Gowan, Katherine and Jones, Kenneth and Schubert, Laura and Doak, Andrea and Estrada-Bernal, Adriana and Davies, Kurtis D and Merrick, Daniel T and Bunn, Paul A and Purcell, W. Tom and Dziadziuszko, Rafal and Varella-Garcia, Marileila and Aisner, Dara L and Camidge, D. Ross and Doebele, Robert C
Clinical cancer research, ISSN 1078-0432, 07/2018, Volume 24, Issue 14, pp. 3334 - 3347
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Molecular Targeted Therapy | Biomarkers, Tumor | Anaplastic Lymphoma Kinase - genetics | DNA Copy Number Variations | Young Adult | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - chemistry | Protein-Tyrosine Kinases - chemistry | Adult | Female | Anaplastic Lymphoma Kinase - chemistry | Lung Neoplasms - genetics | Computational Biology - methods | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Drug Resistance, Neoplasm - genetics | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | High-Throughput Nucleotide Sequencing | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung Neoplasms - diagnosis | Tyrosine | Neuregulin 1 | Epidermal growth factor receptors | Genes | Lung cancer | Non-small cell lung carcinoma | Drug resistance | Kinases | Patients | ErbB-2 protein | Gene fusion | Genetic screening | Gene sequencing | Polymerase chain reaction | β-catenin | Ret protein | Experimental design | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Proto-oncogenes | Index Medicus | non-small cell lung cancer | ALK | tyrosine kinase inhibitor | ROS1 | acquired resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Beneath the Blood Brain Barrier: The Challenge of Diagnosis and Management of Central Nervous System Involvement in ALK-Positive Lung Cancer
by Dziadziuszko, Rafal and Jassem, Jacek
Journal of thoracic oncology, ISSN 1556-0864, 12/2013, Volume 8, Issue 12, pp. 1465 - 1466
crizotinib | leptomeningeal carcinomatosis | intramedullary spinal cord metastases | anaplastic lymphoma kinase | Medical University of Gdańsk | Gdańsk | Intramedullary spinal cord metastases | Crizotinib Department of Oncology and Radiotherapy | Poland | Anaplastic lymphoma kinase | Leptomeningeal carcinomatosis | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Spinal Neoplasms - secondary | Receptor Protein-Tyrosine Kinases - genetics | Gene Rearrangement | Humans | Female | Lung Neoplasms - pathology | Male | Meningeal Carcinomatosis - secondary
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Welcome to the 4th European lung cancer conference
by Felip, Enriqueta and Dziadziuszko, Rafal
Journal of thoracic oncology, ISSN 1556-0864, 2014, Volume 9, Issue 4, p. S6
Journal Article
Details down arrow
10. Full Text Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
by Fred R. Hirsch and Marileila Varella-Garcia and Paul A. Bunn Jr and Wilbur A. Franklin and Rafal Dziadziuszko and Nick Thatcher and Alex Chang and Purvish Parikh and José Rodrigues Pereira and Tudor Ciuleanu and Joachim von Pawel and Claire Watkins and Angela Flannery and Gillian Ellison and Emma Donald and Lucy Knight and Dinah Parums and Nicholas Botwood and Brian Holloway
Journal of clinical oncology, ISSN 0732-183X, 11/2006, Volume 24, Issue 31, pp. 5034 - 5042
Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Carcinoma, Non-Small-Cell Lung - chemistry | ras Proteins | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Antineoplastic Agents - therapeutic use | Adult | Female | Lung Neoplasms - chemistry | Biomarkers, Tumor - analysis | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Proto-Oncogene Proteins c-akt - analysis | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
by Drilon, Alexander and Siena, Salvatore and Dziadziuszko, Rafal and Barlesi, Fabrice and Krebs, Matthew G and Shaw, Alice T and de Braud, Filippo and Rolfo, Christian and Ahn, Myung-Ju and Wolf, Jürgen and Seto, Takashi and Cho, Byoung Chul and Patel, Manish R and Chiu, Chao-Hua and John, Thomas and Goto, Koichi and Karapetis, Christos S and Arkenau, Hendrick-Tobias and Kim, Sang-We and Ohe, Yuichiro and Li, Yu-Chung and Chae, Young K and Chung, Christine H and Otterson, Gregory A and Murakami, Haruyasu and Lin, Chia-Chi and Tan, Daniel S W and Prenen, Hans and Riehl, Todd and Chow-Maneval, Edna and Simmons, Brian and Cui, Na and Johnson, Ann and Eng, Susan and Wilson, Timothy R and Doebele, Robert C and trial investigators and Trial Investigators
The lancet oncology, ISSN 1470-2045, 02/2020, Volume 21, Issue 2, pp. 261 - 270
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Benzamides - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents - adverse effects | Female | Biomarkers, Tumor - antagonists & inhibitors | Benzamides - adverse effects | Lung Neoplasms - genetics | Proto-Oncogene Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Gene Fusion | Proto-Oncogene Proteins - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Progression-Free Survival | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Clinical Trials, Phase I as Topic | Indazoles - therapeutic use | Clinical Trials, Phase II as Topic | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
by Ceresoli, Giovanni L and Aerts, Joachim G and Dziadziuszko, Rafal and Ramlau, Rodryg and Cedres, Susana and van Meerbeeck, Jan P and Mencoboni, Manlio and Planchard, David and Chella, Antonio and Crinò, Lucio and Krzakowski, Maciej and Rüssel, Jörn and Maconi, Antonio and Gianoncelli, Letizia and Grosso, Federica
The lancet oncology, ISSN 1470-2045, 12/2019, Volume 20, Issue 12, pp. 1702 - 1709
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Prognosis | Prospective Studies | Follow-Up Studies | Mesothelioma - pathology | Humans | Middle Aged | Carboplatin - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Cisplatin - administration & dosage | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Female | Aged | Mesothelioma, Malignant | Pleural Neoplasms - pathology | Care and treatment | Analysis | Carboplatin | Mesothelioma | Product development | Pemetrexed | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer
by Jassem, Jacek and Dziadziuszko, Rafał
The lancet respiratory medicine, ISSN 2213-2600, 06/2020, Volume 8, Issue 6, pp. 528 - 529
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
by Wrona, Anna and Dziadziuszko, Rafał and Jassem, Jacek
Cancer treatment reviews, ISSN 0305-7372, 12/2018, Volume 71, pp. 59 - 67
Stereotactic radiosurgery | ALK inhibitors | Brain metastases | EGFR inhibitors | Whole brain radiotherapy | Non-small cell lung cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Crizotinib - therapeutic use | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Brain Neoplasms - secondary | Protein Kinase Inhibitors - therapeutic use | Crizotinib - pharmacology | Antineoplastic Agents - pharmacology | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Molecular Targeted Therapy - methods | Oncogenes | Tyrosine | Brain | Chemotherapy | Radiosurgery | Phenols | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Health aspects | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights